Bisphosphonates attenuate age-related muscle decline in Caenorhabditis elegans.

Sarcopenia is a common condition where muscle strength and mass decrease as people age, leading to health risks like falls, disability, and even death. A recent study looked at how an older drug called zoledronic acid (ZA) might help fight this problem in tiny creatures that share similarities with humans when it comes to aging. The researchers tested ZA on these small organisms after they reached adulthood, and found some interesting results: while the highest dose of ZA actually shortened their lifespan (which is not good), a lower dose helped keep muscles healthy for longer without affecting how long they lived. This suggests that with careful dosage adjustments, this drug might help older adults maintain stronger and more resilient muscles as part of an overall strategy to stay active and independent in their later years. The study also discovered specific genes linked to the positive effects seen from ZA treatment on muscle health.

This research paper investigates the effects of age-related muscle decline or sarcopenia and explores potential treatment strategies using a combination of physical activity and targeted nutrition supplementation with zoledronic acid (ZA). Sarcopenia, which affects at least 10% to up to 31% of older populations as comorbidity, is associated with significant healthcare costs and impacts on quality of life. The study employed a microfluidic chip device for assessing lifespan extension (healthspan) in the presence or absence of ZA treatment at various concentrations: 1μM, 10μM, 500μM, etc., and examined its effects on muscle fiber structure using GFP-tagged myofibrils. The results indicated that while higher doses (>10μM) of ZA were lethal to larvae, the lowest tested concentration effectively improved well-organized myofibril structures in adults at days 4 and 6 post-adulthood when compared with untreated controls.